

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): January 28, 2011**

---

**MEDICINOVA, INC.**

**(Exact name of Registrant as Specified in Its Charter)**

---

**DELAWARE**  
**(State or Other Jurisdiction  
of Incorporation)**

**001-33185**  
**(Commission  
File Number)**

**33-0927979**  
**(IRS Employer  
Identification No.)**

**4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO, CA**  
**(Address of Principal Executive Offices)**

**92122**  
**(Zip Code)**

**Registrant's telephone number, including area code: (858) 373-1500**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 28, 2011, Alan W. Dunton, M.D., resigned as a member of the Board of Directors of MediciNova, Inc., a Delaware corporation (the “Company”), with immediate effect. Dr. Dunton’s resignation was not in connection with any known disagreement with the Company on any matter. Following Dr. Dunton’s resignation the Board of Directors reduced the size of the Board of Directors from six to five members.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MEDICINOVA, INC.**

Date: February 1, 2011

By: /s/ Yuichi Iwaki

Name: Yuichi Iwaki, M.D., Ph.D.

Title: President and Chief Executive Officer